ImmunityBio, Inc. (IBRX)
Develops immunotherapies that activate the immune system to fight cancer and infectious diseases.
$6.97-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+194.1%
The outlook
IBRX trades near the middle of its 52-week range with mixed momentum against its moving averages. Analyst coverage leans notably bullish, with an average price target implying substantial upside from current levels. The overall sentiment tilts constructive, though recent price action remains relatively flat.
What’s behind the score
Price trendMixed vs its moving averages
52-week range48% of the way from its 52-week low to high
Price targetAvg target +87% vs current price
Analyst price target
~12-month · 3 analysts$13.00average target+86.5% vs now
Now $6.97
Low $12.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.30B
52-wk high
$12.43
52-wk low
$1.95
50-day avg
$7.75
200-day avg
$5.82
Trailing P/E
—